Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

1.1 Historical Overview of Dendritic Cell Cancer Vaccine
1.2 Dendritic Cell Vaccines: A Revolutionary Cancer Therapy

2.1 Dendritic Cell: Integral Part of Human Immune System
2.2 Effects of Cancer on Dendritic Cell Mediated Immunity

3.1 Process Involved in Manufacturing Dendritic Cell Vaccine
3.2 Understanding Working Mechanism of Dendritic Cell Vaccine against Cancer Cells

4.1 Provenge
4.1.1 Clinical Efficacy
4.1.2 Availability, Dosage & Treatment Schedule
4.1.3 Treatment Cost Analysis
4.1.4 Manufacturing Cost & Market Worth
4.2 Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
4.2.1 Clinical Efficacy
4.2.2 Availability, Dosage & Treatment Schedule
4.3 CreaVax RCC
4.3.1 Availability, Dosage & Treatment Schedule
4.3.2 Manufacturing Cost Process & Involved Technologies

5.1 Sipuleucel-T (Provenge)
5.2 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
5.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

6.1 CreaVax-HCC, CreavAX-PC, CreaVax-BC
6.2 Rocapuldencel-T
6.3 MelCancerVac
6.4 Apceden (Apceden-GBM, Apceden-RCC)
6.5 Vaccell

7.1 Provenge v/s Jevtana
7.1.1 Clinical Efficacy
7.1.2 Treatment Course & Dosage
7.1.3 Therapy Price Analysis
7.2 Provenge v/s Zytiga
7.2.1 Clinical Efficacy
7.2.2 Treatment Course & Dosage
7.2.3 Therapy Price Analysis

8.1 North America
8.2 India
8.3 South Korea
8.4 Japan

9.1 Dendritic Cell Cancer Vaccine with Radiotherapy
9.2 Dendritic Cell Cancer Vaccine with Monoclonal Antibodies

10.1 Global Dendritic Cell Cancer Vaccine Market Trends
10.2 Global Dendritic Cell Vaccine Market Regional Insight
10.2.1 Scope of Dendritic Cell Vaccine Market by Ongoing Researches & Available Advanced Therapies by Region
10.2.2 Scope of Dendritic Cell Vaccine Market by Investments for from Different Sectors
10.2.3 Scope of Reimbursement of Dendritic Cell Cancer Therapy

11.1 Dendritic Cell Vaccine in Stage-III Melanoma
11.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia
11.3 Dendritic Cell Vaccine in Brain Tumor

12.1 Favorable Market Parameters
12.2 Market Growth Challenges

13.1 Technical Advancements in Dendritic Cell Cancer Vaccine in Future
13.2 Increase in Prevalence of Cancer Providing a Large Target Patient Base for Dendritic Cell Cancer Vaccine in Future

15.1 Unknown
15.2 Research
15.3 Preclinical
15.4 Clinical
15.5 Phase-I
15.6 Phase-I/II
15.7 Phase-II
15.8 Phase-II/III
15.9 Phase-III

16.1 3M Company
16.2 Activartis
16.3 Argos Therapeutics
16.4 Batavia Bioservices
16.5 Bellicum Pharmaceuticals
16.6 Creagene
16.7 DanDrit Biotech
16.8 DCPrime
16.9 Dendreon Corporation
16.10 Elios Therapeutics
16.11 ImmunoCellular Therapeutics
16.12 Immunicum
16.13 Kiromic
16.14 Medigene
16.15 Merck
16.16 Northwest Biotherapeutics
16.17 Glaxo Smith Kline
16.18 ImmunoCellular Therapeutics
16.19 SOTIO
16.20 Tella Incorporation
16.21 Theravectys
16.22 Vaxil BioTherapeutics

Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development
Figure 2-1: Dendritic Cell in Human Immune System
Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression
Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines
Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine
Figure 4-1:  Provenge: Efficacy on the Basis of Clinical Trials
Figure 4-2: Provenge – Number of Autologous CD54+ Activated Cells (Million)
Figure 4-3: Provenge – Dosage Administration (Minutes)
Figure 4-4: Provenge - Average Duration of Therapy
Figure 4-5: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
Figure 4-6: Provenge – Average Cost (US$/Patient), 2018
Figure 4-7: Provenge – Therapy Cost Analysis (US$/Treatment Course), 2018
Figure 4 8: Provenge – Company’s Expenditure in Drug Development & Therapy Market Value (US$ Billion)
Figure 4-9: Apceden – Median Progression-Free Survival in Patients with Solid Tumors (Number of Months), 2018
Figure 4-10: Apceden – Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months), 2018
Figure 4-11: Apceden v/s Provenge – Adverse Side Effects (%), 2018
Figure 4-12: Apceden – Availability of Vial & Vials Required in Apceden Therapy, 2018
Figure 4-13: Apceden – Intervals Between Multiple Doses of Treatment
Figure 4-14: CreaVax RCC – Approval Analysis by Phase (Year)
Figure 4-15: CreaVax RCC – Treatment Course Duration (Weeks), 2018
Figure 4-16: CreaVax RCC – Vial Composition Analysis (mL/Dose & Number of Cells/Dose), 2018
Figure 4-17: South Korea - CreaVax RCC Patent Cost (US$)
Figure 4-18: South Korea – Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US$)
Figure 7-1: Provenge v/s Jevtana – Median Progression Free Survival (Months)
Figure 7-2: Provenge v/s Jevtana – Overall Survival (Months)
Figure 7-3: Provenge v/s Jevtana – Discontinuation of Treatment in Patients due to Adverse Effects (%)
Figure 7-4: Provenge v/s Jevtana – Average Treatment Cycles in Complete Therapy (By Number)
Figure 7-5: Provenge v/s Jevtana – Price Analysis (US$/Unit), 2018
Figure 7-6: Provenge v/s Jevtana – Price Analysis (US$/Infusion), 2018
Figure 7-7: Provenge v/s Jevtana – Average Treatment Cost Analysis (US$), 2018
Figure 7-8: Provenge v/s Zytiga – Median Progression Free Survival (Months)
Figure 7-9: Provenge v/s Zytiga – Therapy Cost Analysis (US$), 2018
Figure 8-1: Global – Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2018
Figure 8-2: India – Average Lung Cancer Prevalence per Year
Figure 8-3: India – Lung Cancer Prevalence by Stage (%), 2018
Figure 8-4: India – Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2018
Figure 8-5: India – Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2018
Figure 8-6: India – Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2018
Figure 8-7: India – Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2018
Figure 8-8: South Korea – Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
Figure 8-9: South Korea – CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2018
Figure 8-10: South Korea – Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2018
Figure 8-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
Figure 8-12: South Korea – Renal Cancer Prevalence by Gender, 2018
Figure 8-13: Japan – Epidemiology of Cancer by Gender (%), 2018
Figure 8-14: Japan – Epidemiology of Cancer (Number of Patients), 2018
Figure 8-15: Japan – Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2018
Figure 8-16: Japan – Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2018
Figure 8-17: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2018
Figure 8-18: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
Figure 8 19: Japan – Vaccell Potential Patient Base by New Incidences, 2018
Figure 10-1: Global - Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches
Figure 10-2: Global – Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies
Figure 10-3: Global – Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials
Figure 10-4: Global – Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization
Figure 12-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market
Figure 13-1: Global – Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)
Figure 14-1: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (%), 2018 till 2024
Figure 14-2: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 14-3: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (%), 2018 till 2024
Figure 14-4: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 14-5: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Region/Country (%), 2018 till 2024
Figure 14-6: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company (%), 2018 till 2024
Figure 16-1: Argos Therapeutics- Clinical Pipeline
Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 16-3: DCPrime Clinical Pipeline
Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 16-5: Immunicum Clinical Pipeline
Figure 16-6: Medigene Clinical Pipeline
Figure 16-7: Northwest Biotherapeutics Clinical Pipeline
Figure 16-8: SOTIO Clinical Pipeline